193 related articles for article (PubMed ID: 17609664)
1. Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil.
Chen CC; Chen LT; Tsou TC; Pan WY; Kuo CC; Liu JF; Yeh SC; Tsai FY; Hsieh HP; Chang JY
Br J Cancer; 2007 Aug; 97(3):334-44. PubMed ID: 17609664
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification.
Chen CC; Chu CB; Liu KJ; Huang CY; Chang JY; Pan WY; Chen HH; Cheng YH; Lee KD; Chen MF; Kuo CC; Chen LT
Biochem Pharmacol; 2013 Oct; 86(7):872-87. PubMed ID: 23933386
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
[TBL] [Abstract][Full Text] [Related]
4. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate.
Hill BT; Shellard SA; Hosking LK; Dempke WC; Fichtinger-Schepman AM; Tone T; Scanlon KJ; Whelan RD
Cancer Res; 1992 Jun; 52(11):3110-8. PubMed ID: 1591724
[TBL] [Abstract][Full Text] [Related]
6. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic basis of a combination D-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo.
Chen SJ; Kuo CC; Pan HY; Tsou TC; Yeh SC; Chang JY
Biochem Pharmacol; 2015 May; 95(1):28-37. PubMed ID: 25801007
[TBL] [Abstract][Full Text] [Related]
8. Biochemical characterization of cisplatin-resistance in MKN-45 human stomach adenocarcinoma cell line.
Hong WS; Son YS
Anticancer Res; 1996; 16(5A):3031-6. PubMed ID: 8917423
[TBL] [Abstract][Full Text] [Related]
9. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
Lai SL; Hwang J; Perng RP; Whang-Peng J
Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
[TBL] [Abstract][Full Text] [Related]
10. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
Meijer C; Mulder NH; Timmer-Bosscha H; Sluiter WJ; Meersma GJ; de Vries EG
Cancer Res; 1992 Dec; 52(24):6885-9. PubMed ID: 1458477
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
Stordal BK; Davey MW; Davey RA
Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
[TBL] [Abstract][Full Text] [Related]
12. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
[TBL] [Abstract][Full Text] [Related]
13. Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line.
Esaki T; Nakano S; Masumoto N; Fujishima H; Niho Y
Int J Cancer; 1996 Feb; 65(4):479-84. PubMed ID: 8621231
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines.
Noordhuis P; Laan AC; van de Born K; Losekoot N; Kathmann I; Peters GJ
Biochem Pharmacol; 2008 Jul; 76(1):53-61. PubMed ID: 18508032
[TBL] [Abstract][Full Text] [Related]
15. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
16. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor.
Nishikawa K; Rosenblum MG; Newman RA; Pandita TK; Hittelman WN; Donato NJ
Cancer Res; 1992 Sep; 52(17):4758-65. PubMed ID: 1380890
[TBL] [Abstract][Full Text] [Related]
17. Cross-resistance of platinum derivatives in H-1R, a cisplatin-resistant cell line.
Negoro K; Yamano Y; Nakashima D; Saito K; Nakatani K; Shiiba M; Bukawa H; Yokoe H; Uzawa K; Wada T; Tanzawa H; Fujita S
Oncol Rep; 2009 Feb; 21(2):443-9. PubMed ID: 19148521
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
Tanaka T; Masuda H; Naito M; Tamai H
Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
[TBL] [Abstract][Full Text] [Related]
19. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin.
Kasahara K; Fujiwara Y; Nishio K; Ohmori T; Sugimoto Y; Komiya K; Matsuda T; Saijo N
Cancer Res; 1991 Jun; 51(12):3237-42. PubMed ID: 1645616
[TBL] [Abstract][Full Text] [Related]
20. Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP.
Zhan M; Liu X
Chin Med J (Engl); 1999 Apr; 112(4):336-9. PubMed ID: 11593534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
